Look­ing for the next big break­through in CAR-T, Mike Gilman de­buts Ob­sid­i­an with $49.5M round

Biotech en­tre­pre­neur Michael Gilman is now on to his fourth start­up Suzanne Kre­it­er, Boston Globe

Over the past cou­ple of years, the pi­o­neers in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA